# Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

> **NCT04101357** · PHASE1,PHASE2 · TERMINATED · sponsor: **BioNTech SE** · enrollment: 54 (actual)

## Conditions studied

- Solid Tumor
- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** BNT411
- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04101357
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-19
- **Primary completion:** 2024-01-19
- **Final completion:** 2024-05-23
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04101357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04101357, "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04101357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*